The market has climbed 2.2% in the last 7 days and is up 25% over the past year, with earnings expected to grow by 19% annually in the coming years. In such a robust market, identifying stocks with strong fundamentals and growth potential is key, especially when considering penny stocks—companies that are smaller or less established but can offer significant value. Despite being an outdated term, penny stocks remain a relevant investment area for those seeking opportunities in companies with sound balance sheets and promising growth trajectories.

Let's take a closer look at a couple of our picks from the screened companies.

Niagen Bioscience (NAGE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products with a market cap of $275.35 million.

Operations: The company's revenue is primarily derived from Consumer Products at $98.58 million, followed by Ingredients contributing $29.07 million, and Analytical Reference Standards and Services generating $2.69 million.

Market Cap: $275.35M

Niagen Bioscience, Inc. is a promising prospect in the penny stock arena, with a market cap of US$275.35 million and no debt burden. The company reported first-quarter 2026 sales of US$31.47 million, reflecting steady revenue streams from its consumer products and ingredients divisions. Recent strategic partnerships and product innovations like the Niagen At-Home Injection Kit highlight its focus on expanding access to healthy aging solutions while diversifying distribution channels through alliances with Olympia Pharmaceuticals and OneSpaWorld. Despite large one-off gains impacting recent results, Niagen's earnings have shown consistent growth over the past five years, supported by a high return on equity of 22.6%.

Rocket Pharmaceuticals (RCKT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company specializing in the development, manufacturing, and commercialization of genetic therapies for rare and severe diseases in the United States, with a market cap of approximately $300.28 million.

Operations: Rocket Pharmaceuticals does not report any revenue segments.

Market Cap: $300.28M

Rocket Pharmaceuticals, Inc., with a market cap of US$300.28 million, is pre-revenue and faces challenges typical for penny stocks in the biotech sector. The company has less than a year of cash runway based on current free cash flow trends and has experienced significant insider selling recently. Despite these hurdles, Rocket's financial position is bolstered by short-term assets exceeding liabilities and being debt-free. Notably, the FDA's accelerated approval of KRESLADI for treating severe leukocyte adhesion deficiency-I marks a critical milestone that could enhance future prospects if clinical benefits are confirmed through ongoing studies.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based therapeutics for cancer treatment in the United States with a market cap of $251.71 million.

Operations: The company generated $157.08 million from its segment dedicated to the development and commercialization of monoclonal antibody-based therapeutics.

Market Cap: $251.71M

MacroGenics, Inc., with a market cap of US$251.71 million, operates in the biopharmaceutical sector and is currently unprofitable. Despite this, the company is debt-free and has not experienced significant shareholder dilution over the past year. Its financial position is supported by short-term assets exceeding liabilities and a cash runway extending beyond one year based on current free cash flow. Recent developments include an FDA decision to lift a partial clinical hold on its Phase 2 LINNET study for lorigerlimab, which could influence future outcomes as new participants are enrolled under revised protocols addressing potential toxicities.

Seize The Opportunity

• Investigate our full lineup of 329 US Penny Stocks right here.
• Curious About Other Options? Uncover 24 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.